Name:	dvax_PotentialMilestonePaymentAmount
Namespace Prefix:	dvax_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research Collaboration and License Agreement Period

+ References

No definition available.

+ Details

Name:	dvax_ResearchCollaborationAndLicenseAgreementPeriod
Namespace Prefix:	dvax_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue Recognition, Period

+ References

No definition available.

+ Details

Name:	dvax_RevenueRecognitionPeriod
Namespace Prefix:	dvax_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 910

-SubTopic 310

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6471494&loc=d3e49354-109356

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph c

-Article 5

+ Details

Name:	us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name:	us-gaap_GrantsReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_ProductInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Collaborative Research, Development, and License Agreements - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended		12 Months Ended			1 Months Ended	3 Months Ended		9 Months Ended			1 Months Ended	12 Months Ended	3 Months Ended		9 Months Ended							1 Months Ended
	Dec. 31, 2008 Glaxo, Smith, Kline Project	Sep. 30, 2013 Glaxo, Smith, Kline	Sep. 30, 2012 Glaxo, Smith, Kline	Sep. 30, 2013 Glaxo, Smith, Kline	Sep. 30, 2012 Glaxo, Smith, Kline	Dec. 31, 2011 Glaxo, Smith, Kline	Dec. 31, 2012 Glaxo, Smith, Kline	Dec. 31, 2011 Glaxo, Smith, Kline Expansion	Sep. 30, 2013 Glaxo, Smith, Kline Maximum	Sep. 30, 2013 Glaxo, Smith, Kline Maximum Annual net sales milestones achieved	Sep. 30, 2006 Astra Zeneca	Sep. 30, 2013 Astra Zeneca	Sep. 30, 2012 Astra Zeneca	Sep. 30, 2013 Astra Zeneca	Sep. 30, 2012 Astra Zeneca	Dec. 31, 2012 Astra Zeneca	Oct. 31, 2011 Amendment	Dec. 31, 2011 Amendment	Dec. 31, 2012 Amendment Advance the program following completion of Phase 2a	Mar. 31, 2012 Amendment Advance the program following completion of Phase 2a	Sep. 30, 2013 Amendment Advance the program following completion of Phase 2a	Sep. 30, 2013 Amendment Maximum Advance the program following completion of Phase 2a	Jun. 30, 2012 Autoimmune Disease National Institutes of Health	May 31, 2012 Rheumatoid Arthritis National Institutes of Health	Jul. 31, 2011 Skin Autoimmune Inflammation National Institutes of Health	Aug. 31, 2010 HBV National Institutes of Health	Jul. 31, 2010 HPV National Institutes of Health	Sep. 30, 2008 ISS Technology National Institutes of Health	Sep. 30, 2013 Hepatic Fibrosis and Cirrhosis National Institutes of Health
Product Information [Line Items]
Number of programs for research and early clinical development	4
Potential milestone payment									$ 125,000,000	$ 60,000,000
Collaboration Revenue	10,000,000	357,000	357,000	1,071,000	1,071,000							180,000	180,000	540,000	540,000		3,000,000		6,000,000	2,600,000
Revenue from milestone payment						12,000,000		3,000,000				573,000	513,000	1,738,000	1,991,000						20,000,000	100,000,000
Deferred revenue recognition period		7 years		7 years								50 months		50 months
Deferred revenue		3,200,000		3,200,000			4,200,000					5,700,000		5,700,000		7,700,000
Research collaboration and license agreement period											3 years
Cost of clinical development activities																		20,000,000
Grants receivable																							600,000	400,000	600,000	1,400,000	600,000		200,000
Contract agreement period																												5 years
Contract awarded to develop technology																												$ 17,000,000